Repatha Global Regulatory Status

FDA Approval: Timeline and Label Milestones

The FDA approved Repatha on August 27, 2015, under Biologics License Application (BLA) 125522 [1]. The initial indication covered adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and clinical atherosclerotic cardiovascular disease (ASCVD) who required additional LDL-C lowering on maximally tolerated statin therapy. Repatha received priority review, and the FDA's decision came roughly six weeks ahead of the Prescription Drug User Fee Act target date.

The original label was confined to lipid lowering. It did not carry a cardiovascular outcomes claim. That changed on December 1, 2017, when the FDA approved a supplemental BLA adding a specific indication for reducing the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease [2]. This expansion rested entirely on data from the FOURIER trial, the largest randomized controlled trial ever conducted with a PCSK9 inhibitor at that time [3].

A pediatric indication followed. In 2021, the FDA extended approval to patients aged 10 years and older with HeFH, making Repatha one of a small number of biologic lipid therapies available to adolescents [4]. Amgen filed this application using pharmacokinetic bridging data and the HAUSER-RCT trial in pediatric HeFH patients, which showed a 38.3% reduction in LDL-C versus placebo at 24 weeks [5].

EMA Authorization and the European Label

The European Medicines Agency granted marketing authorization for Repatha on July 17, 2015, roughly six weeks before the FDA's decision [6]. The Committee for Medicinal Products for Human Use (CHMP) recommended approval based on the LAPLACE-2, RUTHERFORD-2, TESLA Part B, and MENDEL-2 phase III trials, which collectively enrolled over 6,000 patients across HeFH, HoFH, and statin-intolerant populations.

The EMA label initially matched the FDA's scope: LDL-C reduction in patients inadequately controlled on diet and maximally tolerated statins. A type II variation in 2018 added the cardiovascular risk reduction indication, aligned with FOURIER findings. One difference persists between the two labels. The EMA explicitly lists "primary hypercholesterolaemia (non-familial)" alongside mixed dyslipidaemia as a standalone indication, a distinction the FDA label addresses through its broader ASCVD and statin-adjunct framing [6].

Pricing and reimbursement remain more fragmented across Europe than in the United States. Germany's G-BA assigned an added-benefit rating for the HeFH population but not for broader hypercholesterolemia without prior cardiovascular events. England's National Institute for Health and Care Excellence (NICE) recommended Repatha only after a confidential price discount and restricted it to patients with LDL-C persistently above 4.0 mmol/L on maximum tolerated lipid-lowering therapy [7].

Regulatory Status in Japan, Canada, and Australia

Japan's Ministry of Health, Labour and Welfare (MHLW) approved evolocumab in January 2016 for familial hypercholesterolemia and high-risk hypercholesterolemia. Japan was among the first Asian markets to authorize a PCSK9 inhibitor. The Japanese label carries a dosing schedule identical to the global label: 140 mg every two weeks or 420 mg monthly.

Health Canada authorized Repatha in September 2015. The Canadian label covers HeFH, HoFH, and patients with clinical ASCVD, mirroring the post-FOURIER FDA language after a 2018 update. The Canadian Drug Expert Committee (CDEC) issued a conditional recommendation for reimbursement, limiting public coverage to patients with familial hypercholesterolemia or very high cardiovascular risk who have failed statins and ezetimibe [8].

Australia's Therapeutic Goods Administration (TGA) registered Repatha in August 2015. Subsidized access through the Pharmaceutical Benefits Scheme (PBS) requires documented statin intolerance or treatment failure in FH patients. The PBS listing does not extend to the general ASCVD population without familial hypercholesterolemia.

The FOURIER Trial and Its Regulatory Impact

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) randomized 27,564 patients with established atherosclerotic disease and LDL-C of 70 mg/dL or higher, despite statin therapy, to evolocumab or placebo [3]. Median follow-up was 2.2 years. The trial met its primary composite endpoint. Evolocumab reduced the risk of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). The key secondary endpoint (cardiovascular death, MI, or stroke) dropped by 20% (HR 0.80, 95% CI 0.73 to 0.88, P<0.001) [3].

LDL-C fell from a median baseline of 92 mg/dL to 30 mg/dL at 48 weeks in the evolocumab arm. That 59% reduction gave regulators confidence in the LDL hypothesis at levels far below prior therapeutic targets. Dr. Marc Sabatine, the trial's principal investigator, stated: "These data establish that inhibiting PCSK9 with evolocumab on a background of statin therapy reduces cardiovascular events, and that the benefits grew over time" [3].

The trial's safety profile shaped every label expansion that followed. Injection-site reactions occurred in 2.1% of the evolocumab group versus 1.6% on placebo. Neurocognitive adverse events were reported at similar rates in both arms (1.6% vs. 1.5%), which addressed a pre-existing concern raised during the FDA's 2015 advisory committee meeting [3]. No signal for new-onset diabetes emerged, a finding that separated PCSK9 inhibitors from the known diabetogenic risk of high-intensity statins.

Current Prescribing Information and Label Details

The 2024 Repatha U.S. prescribing information lists four distinct populations [9]:

Adults with established ASCVD, to reduce the risk of MI, stroke, and coronary revascularization. Adults with primary hyperlipidemia (including HeFH), to reduce LDL-C as an adjunct to diet and maximally tolerated statin therapy. Adults and pediatric patients aged 10 and older with HeFH, when additional LDL-C lowering is needed. Adults and pediatric patients aged 10 and older with HoFH, as adjunct to diet and other LDL-lowering therapies.

Dosing is 140 mg subcutaneous injection every two weeks, or 420 mg once monthly using three consecutive autoinjector pens or the single-dose SureClick autoinjector. The 420 mg once-monthly option was added after the TAUSSIG open-label extension study confirmed comparable LDL-C reductions with monthly dosing [10].

Contraindications remain limited to a history of serious hypersensitivity reaction to evolocumab or any excipient. The warnings and precautions section flags allergic reactions (rash, urticaria, hypersensitivity vasculitis) and latex sensitivity in the needle cover of the prefilled syringe and SureClick autoinjector. The label does not carry a boxed warning.

The 2020 American College of Cardiology/American Heart Association (ACC/AHA) Consensus Decision Pathway states: "For patients at very high risk whose LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is reasonable" [11]. That document does not favor evolocumab over alirocumab; it treats both as interchangeable options in the same pharmacologic class.

Post-Marketing Safety Surveillance

The FDA's Sentinel System and Amgen's periodic safety update reports (PSURs) through 2025 have not identified major new safety signals beyond the known adverse-reaction profile [12]. The EMA's pharmacovigilance risk assessment committee (PRAC) reached the same conclusion in its most recent periodic review.

Long-term data from FOURIER's open-label extension (FOURIER-OLE) followed 6,635 patients for a median of 5 years. Cardiovascular event rates continued to separate in favor of those originally assigned to evolocumab. The all-cause mortality hazard ratio was 0.93 (95% CI 0.82 to 1.05), numerically lower but not statistically significant [13]. No increase in cancer, hemorrhagic stroke, neurocognitive disorders, or cataracts appeared over 5 years of sustained LDL-C levels below 30 mg/dL [13].

Injection-site reactions remain the most common treatment-related adverse event, affecting roughly 3% of patients in long-term registries. Anti-drug antibodies developed in 0.3% of patients in the pooled clinical trial database, with no neutralizing antibodies detected that affected efficacy [9]. The absence of neutralizing antibodies is notable for a biologic administered over years, since immunogenicity can erode drug concentrations over time.

Dr. Robert Giugliano, a co-investigator on FOURIER-OLE, noted: "Five years of follow-up confirm that very low LDL-C levels achieved with evolocumab are safe, and the cardiovascular benefits continue to accrue with longer treatment duration" [13].

Guideline Integration Across Major Societies

Evolocumab occupies a defined step in every major lipid guideline published since 2018. The 2018 ACC/AHA cholesterol guideline positions PCSK9 inhibitors as third-line agents after high-intensity statins and ezetimibe in patients whose LDL-C remains 70 mg/dL or above with established ASCVD, or 100 mg/dL or above without prior events but with familial hypercholesterolemia [11]. The European Society of Cardiology (ESC) 2019 dyslipidaemia guidelines set an LDL-C target of <55 mg/dL for very-high-risk patients, a threshold that often requires PCSK9 inhibition to reach [14].

The National Lipid Association (NLA) 2023 recommendations moved PCSK9 inhibitors slightly earlier in the treatment algorithm for patients with recent acute coronary syndrome, citing data showing that early initiation (within 1 to 4 weeks of the event) produced greater absolute risk reductions than delayed starts [15]. This shift reflects accumulating evidence that the benefit of aggressive LDL-C lowering is time-dependent.

Coverage varies considerably by insurer and market. In the U.S., most commercial and Medicare Part D plans require prior authorization and documented failure of or intolerance to high-intensity statin plus ezetimibe. Step-therapy requirements have loosened since 2019, when Amgen reduced Repatha's list price by 60% to $5,850 per year [16]. That price cut coincided with the formation of the Institute for Clinical and Economic Review (ICER) revised value-based benchmark, which had set a threshold of roughly $8,300 per quality-adjusted life year gained.

What the Regulatory Record Means for Prescribers

Repatha's regulatory path is straightforward. Initial approval for lipid lowering, followed by a cardiovascular outcomes claim built on a single large, well-powered trial. The label has broadened consistently, adding pediatric indications and the monthly dosing option, without new restrictions or risk evaluation and mitigation strategies (REMS).

Prescribers ordering evolocumab can point to over a decade of regulatory review across more than 60 countries, a 27,564-patient outcomes trial, and 5-year open-label safety data showing no emergent risks at LDL-C levels below 30 mg/dL. The practical barrier remains access. Prior authorization requirements and formulary position, not regulatory status, are what delay PCSK9 inhibitor starts in clinical practice. A 2022 analysis in JAMA Cardiology found that 53% of initial PCSK9 inhibitor prescriptions in the U.S. were rejected or required appeal, despite meeting guideline criteria [17]. Addressing that gap is an administrative problem, not a scientific one.